Adherence of pharmacoeconomic studies to national guidelines in the Netherlands

Pharmacy World and Science

Volumn 27, Issue 5, 2005, Pages 364-370

  Atthobari, Jarir ^a   Bos, Jasper M ^a   Boersma, Cornelis ^a   Brouwers, Jacobus R B J ^a   De Jong Van Den Berg, Lolkje T W ^a   Postma, Maarten J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Adherence to guidelines; Guidelines; Pharmacoeconomics; Review; The Netherlands

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BUDESONIDE; COLLAGENASE; COUMARIN DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DITHRANOL; EMEDASTINE; ENTACAPONE; ETANERCEPT; EXEMESTANE; FLUTICASONE; FOLIC ACID; GALANTAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; ITRACONAZOLE; LEVOCABASTINE; MEGESTROL; MENINGOCOCCUS VACCINE; PAPAVERINE; POLYSACCHARIDE VACCINE; RANITIDINE; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TERBINAFINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ACUTE DISEASE; ALLERGIC CONJUNCTIVITIS; ALZHEIMER DISEASE; ASTHMA; BREAST CANCER; CANCER CHEMOTHERAPY; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CHRONIC DISEASE; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; DECUBITUS; DIABETIC NEPHROPATHY; ERECTILE DYSFUNCTION; HEALTH CARE COST; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INTERMETHOD COMPARISON; MAJOR DEPRESSION; MEDICAL RESEARCH; MENINGOCOCCOSIS; NETHERLANDS; NEURAL TUBE DEFECT; OINTMENT; PARKINSON DISEASE; PHARMACOECONOMICS; PRACTICE GUIDELINE; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; RHINOSINUSITIS; SENSITIVITY ANALYSIS; SEXUALLY TRANSMITTED DISEASE; SINUSITIS; STREPTOCOCCUS INFECTION; TOENAIL ONYCHOMYCOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DRUG THERAPY; ECONOMICS, PHARMACEUTICAL; GUIDELINE ADHERENCE; HUMANS; NETHERLANDS; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC;

EID: 28844457527     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-005-7904-y     Document Type: Review

References (52)

1. GO Delwel MJ Sprenger 2002 Pharmacoeconomic evaluations of new drugs: potential key to a more efficient allocation of the health care budget Ned Tijdschr Geneeskd 146 23 1068 71 (in Dutch)
2. J Hjelmgren F Berggren F Andersson 2001 Health economic guidelines: similarities, differences and some implications Value Health 4 3 225 50
3. College voor zorgverzekeringen (Health Care Insurance Board) 1999 Richtlijnen voor farmaco-economisch onderzoek. (Dutch guideline for pharmacoeconomic research) College voor zorgverzekeringen Amstelveen
4. MJ Nuijten MJ Brorens YA Hekster 1998 Reporting format for economic evaluation. Part I: Application to the Dutch healthcare system Pharmacoeconomics 14 2 159 63
5. MJ Nuijten MH Pronk MJ Brorens 1998 Reporting formats for economic evaluation. Part II Focus on modelling studies Pharmacoeconomics 14 3 259 68
6. MJ Postma JJ Kwik WJ Rutten LTW de Jong-van den Berg JRBJ Brouwers 2002 Overeenkomsten tussen richtlijnen voor farmaco-economisch onderzoek en eerder gepubliceerde gezonheideconomische evaluaties [Agreement between guidelines for pharmaco-economic research and never-before-published health-economics evaluations] Ned Tijdschr Geneeskd 146 23 1082 7
7. MJ Postma J Kruidhof LTW de Jong-van den Berg JRBJ Brouwers 2002 Het groeiende belang van kosteneffectiviteitsanalyses. Theorie en praktijk van het farmaco-economisch onderzoek (The increasing importance of cost effectiveness analysis. Theory and practice of pharmacoeconomic research) Pharmaceutisch Weekblad 137 45 1582 6
8. L Annemans JM Bos MJ Postma 2003 Discounting health effects in pharmaco-economic evaluations; some additional elements to consider ISPOR Connections 9 4 3 5
9. A Lazaro 2002 Theoretical arguments for the discounting of health consequences. Where do we go from here? Pharmacoeconomics 20 14 943 61
10. R Welte HH Konig R Leidl 2000 The costs of health damage and productivity losses attributable to cigarette smoking in Germany Eur J Public Health 10 1 31 8
11. WJ Meerding M Van Ballegooijen MPM Burger 2002 Human papillomavirus testing for triage of women referred because of abnormal smears: a decision analysis considering outcomes and costs J Clin Epidemiol 55 1025 32
12. MA Koopmanschap FFH Rutten BM Van Ineveld 1995 The friction cost method for measuring indirect cost of disease J Health Econ 14 171 89
13. BA Van Hout ML Simoons 2001 Cost effectiveness of HMG coenzyme reductase inhibitors; whom to treat? Eur Heart J 22 9 751 61
14. M Akazawa JL Sindelar D Paltiel 2003 Economic costs of influenza-related work absenteism Value Health 6 107 15
15. College voor zorgverzekeringen (Health Care Insurance Board) 2001 Farmacotherapeutisch Kompas 2002 (Pharmacotherapeutic Compass) College voor Zorgverzekeringen Amstelveen
16. R Welte M Kretzschmar R Leidl 2000 Cost-effectiveness of screening programs for Chlamydia trachomatis: a population-based dynamic approach Sex Transm Dis 27 9 518 29
17. JB Oostenbrink MA Koopmanschap FFH Rutten 2000 Handleiding voor kostenonderzoek; methoden en richtlijnprijzen voor economische evaluaties in de gezondheidszorg [Guidelines for costing research methods and reference prices for economic evaluation in health care] College voor zorgverzekeringen Amstelveen
18. N Van Os LW Niessen HJ Bilo 2000 Diabetes nephropathy in the Netherlands: a cost effectiveness analysis of national clinical guidelines Health Policy 51 3 135 47
19. EA Stolk JJV Busschbach M Caffa 2000 Cost utility analysis of sildenafil compared with papaverine-phentolamine injections BMJ 320 1165
20. EA Joosen JH Reininga JM Manders 2000 Costs and benefits of a test-and-treat strategy in Helicobacter pylori-infected subjects: a prospective intervention study in general practice Eur J Gastroenterol Hepatol 12 3 319 25
21. MJ Postma ML Heijnen JC Jager 2001 Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in the Netherlands Pharmacoeconomics 19 2 215 22
22. CG Pinto A Lafuma F Fagnani 2001 Cost-effectiveness of emedastine versus levocabastine in the treatment of allergic conjunctivitis in 7 European countries Pharmacoeconomics 19 3 255 65
23. JM Bos JS Fennema MJ Postma 2001 Cost-effectiveness of HIV screening of patients attending clinics for sexually transmitted diseases in Amsterdam AIDS 15 15 2031 6
24. JM Bos HC Rümke R Welte 2001 Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program Vaccine 20 1-2 202 7
25. MJ Nuijten P van Iperen C Palmer 2001 Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis Value Health 4 4 316 28
26. R Jansen WK Redekop FF Rutten 2001 Cost-effectiveness of continuous terbinafine compared with intermittent itraconazole in the treatment of dermatophyte toenail onychomycosis: an analysis of based on results from the L.I.ON study Lamisil versus Itraconazole in Onychomycosis Pharmacoeconomics 19 4 401 10
27. JJ Doyle J Casciano S Arikian 2001 A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs Value Health 4 1 16 31
28. E Müller MW van Leen R Bergemann 2001 Economic evaluation of collagenase-containing ointment and hydrocolloid dressing in the treatment of pressure ulcers Pharmacoeconomics 19 12 1209 16
29. IGM Van Valkengoed MJ Postma SA Morré 2001 Cost-effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infections in women by means of home obtained urine specimens Sex Transm Inf 77 276 82
30. P Krijnen CJE Kaandorp EW Steyerberg 2001 Antibiotic prophylaxis for haematogenous bacterial arthritis in-patients with joint disease: a cost effectiveness analysis Ann Rheum Dis 60 359 66
31. G Van den Boom MPMH Rutten-van Mölken J Molema 2001 The Cost-effectiveness of early treatment with Fluticasone propionate 250 μg twice a day in subjects with obstructive airway disease. Results of the DIMCA Program Am J Respir Crit Care Med 164 2057 66
32. MJ Nuijten 2001 Assessment of clinical guidelines for continuation treatment in major depression Value Health 4 4 281 94
33. MJ Postma R Welte JA van den Hoek 2001 Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia Trachomatis Value Health 4 3 266 75
34. GH De Bock AR van Erkel MP Springer J Kievit 2001 Antibiotic prescription for acute sinusitis in otherwise healthy adults. Clinical cure in relation to costs Scand J Prim Health Care 19 1 58 63
35. MJ Nuijten P Engelfriet K Duijn 2001 A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis Pharmacoeconomics 19 10 1051 64
36. N Li M van Agthoven P Willemse C Uyl-de Groot 2001 A cost-utility analysis comparing second-line chemotherapy schemes in-patients with metastatic breast cancer Anticancer Drugs 12 6 533 40
37. JB Oostenbrink MJD Tangelder JJV Busschbach 2001 Cost-effectiveness of oral anticoagulant versus aspirin in-patients after infrainguinal bypass grafting surgery Vasc Surg 34 254 62
38. P Lindgren B Jönsson A Redaelli D Radice 2002 Cost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: a model for Europe and Australia Pharmacoeconomics 20 2 101 8
39. M Hartman M Prins OQ Swinkels 2002 Cost-effectiveness analysis of a psoriasis care instruction programme with dithranol compared with UVB phototherapy and inpatient dithranol treatment Br J Dermatol 147 3 538 44
40. MJ Postma J Londeman M Veenstra Feb 2002 Cost-effectiveness of periconceptional supplementation of folic acid Pharm World Sci 24 1 8 11
41. JM Ten Berg JC Kelder TH Plokker BA van Hout 2002 Costs and effectiveness of using coumarins before, during and after coronary angioplasty Pharmacoeconomics 20 12 847 53
42. JJ Caro M Salas A Ward D Getsios A Mehnert 2002 AHEAD Study Group. Assessment of Health Economics in Alzheimer's Disease. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands Dement Geriatr Cogn Disord 14 2 84 9
43. TR Schermer BP Thoonen G van den Boom 2002 Randomized Controlled Economic Evaluation of Asthma Self-Management in Primary Health Care Am J Respir Crit Care Med 166 1062 72
44. M Van Agthoven CA Uyl-de Groot WJ Fokkens 2002 Cost analysis of regular and filgrastim treatment in-patients with refractory chronic rhinosinusitis Rhinology 40 2 69 74
45. Canadian Coordinating Office for Health Care Technology Assessment. Guideline for economic evaluation of pharmaceuticals: Canada. 1997. Ontario, Canada
46. WJ Edmunds GF Medley DJ Nokes 1999 Evaluating the cost effectiveness of vaccination programmes: a dynamic perspective Stat Med 18 3263 82
47. JF Baladi D Menon N Otten 1998 Use of economic evaluation guidelines: 2 year's experience in Canada Health Econ 7 221 7
48. Australian Commonwealth Department of Health and Ageing 2002 Guidelines for the pharmaceutical industry on preparation of submissions to the pharmaceutical benefits advisory committee Commonwealth Department of Health and Ageing Canberra
49. Ontario Ministry of Health and Long Term Care 1994 Ontario guidelines for economic analysis of pharmaceutical products Ontario-Ministry of Health and Long Term Care Toronto
50. AH Anis Y Gagnon 2000 Using economic evaluations to make formulary coverage decisions. So much for guidelines Pharmacoeconomics 18 1 55 62
51. JL Severens 2001 Economic evaluation in health care: the usefulness of research guidelines Eur J Obst Gyn Reprod Biol 94 5 7
52. Harrison DL. Evaluation and interpretation of pharmacoeconomic literature. www.oupharmacy.com/clinicaladmin/dharrison/coursenotes2/pharmecon